Company: The Roche Group
Liaison(s): Elizabeth St. John
The Roche Group (ROG) is a global leader in pharmaceuticals, diagnostics, and research with a wide portfolio of functional subsidiaries. Roche’s mission is to, “do now what patients need next”, and is coupled to the shifting priorities of healthcare to more predictive and preventative methods. Next-generation sequencing (NGS) is gaining more traction with regards to clinical utility because of its ability to address disease needs at the genomic level with increasing accuracy and feasibility. Our task was to assess market opportunities for NGS in the immuno-oncology (I-O) space. We researched both established and start-up competitors to develop a perspective of the competition level and products within the disease space to identify incumbents, threats, and opportunities. Similarly, we searched clinical trials utilizing NGS devices as an I-O companion diagnostic or in I-O biomarker studies. We conducted primary research by interviewing opinion leaders on the product development side as well as end users; giving us insight into current market trends. We then utilized market research reports and medical evidence to confirm the results and trends from the primary research. Lastly, we generated a market size and potential for use of this class of technology to ultimately be used in I-O diagnostics along the patient journey.